Fritzberg et al., 1982 - Google Patents
Synthesis and Biological Evaluation of Tc-99m N, N′-Bis (mercaptoacetyl)-2, 3-diaminopropanoate: A Potential Replacement for [131I] o-iodohippurateFritzberg et al., 1982
View PDF- Document ID
- 2416836161114036882
- Author
- Fritzberg A
- Kuni C
- Klingensmith W
- Stevens J
- Whitney W
- Publication year
- Publication venue
- Journal of Nuclear Medicine
External Links
Snippet
Synthesisand BiologicalEvaluationof Tc-99m N,N'-Bis(mercaptoacetyl)-2,3- diaminopropanoate:A
PotentialReplacementfor [1 @ 11]oi Page 1 BASICSCIENCES In 1979 Davison and co-workers (1)
introduced a new class of chelating agents for technetium, based on amide nitrogen and thiolate …
- 230000015572 biosynthetic process 0 title description 6
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0476—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody or an immunoglobulin, or a fragment thereof, e.g. a camelised human single domain antibody, or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0474—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
- A61K51/0493—Steroids, e.g. cholesterol, testosterone
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fritzberg et al. | Synthesis and Biological Evaluation of Tc-99m N, N′-Bis (mercaptoacetyl)-2, 3-diaminopropanoate: A Potential Replacement for [131I] o-iodohippurate | |
| Fritzberg et al. | Chemical and biological studies of Tc-99m N, N′-bis (mercaptoacetamido) ethylenediamine: A potential replacement for I-131 iodohippurate | |
| Fritzberg et al. | Synthesis and biological evaluation of technetium-99m MAG3 as a hippuran replacement | |
| Green et al. | Copper (II) bis (thiosemicarbazone) complexes as potential tracers for evaluation of cerebral and myocardial blood flow with PET | |
| Verbruggen et al. | Technetium-99m-L, L-ethylenedicysteine: a renal imaging agent. I. Labeling and evaluation in animals | |
| Nock et al. | Glutathione-mediated metabolism of technetium-99m SNS/S mixed ligand complexes: a proposed mechanism of brain retention | |
| Mallia et al. | Evaluation of 99mTc (CO) 3 complex of 2-methyl-5-nitroimidazole as an agent for targeting tumor hypoxia | |
| AU2001276677B2 (en) | Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex | |
| Baldas et al. | Effect of the Tc-nitrido group on the behaviour of 99mTc-radiopharmaceuticals | |
| Chervu et al. | Technetium-99m-labeled p-aminohippuric acid analog: a new renal agent: concise communication | |
| Chiotellis et al. | 99mTc-labelled N-substituted carbamoyl iminodiacetates: relationship between structure and biodistribution | |
| Samnick et al. | Investigation of iodine-123-labelled amino acid derivatives for imaging cerebral gliomas: uptake in human glioma cells and evaluation in stereotactically implanted C6 glioma rats | |
| Muftuler et al. | 131I labeling of tamoxifen and biodistribution studies in rats | |
| Fritzberg et al. | Synthesisand BiologicalEvaluationof Tc-99m N, N'-Bis (mercaptoacetyl)-2, 3-diaminopropanoate: A PotentialReplacementfor [1@ 11] o-iodohippurate | |
| US5079346A (en) | Gallium-labelled imaging agents | |
| Mirković et al. | Novel tetradentate diamine dioxime ligands: synthesis, characterization and in vivo behavior of their 99mTc‐complexes | |
| Pervez et al. | 188 Rhenium-EDTMP: A potential therapeutic bone agent | |
| Mallia et al. | Comparing hypoxia‐targeting potential of 99mTc (CO) 3‐labeled 2‐nitro and 4‐nitroimidazole | |
| Bormans et al. | Evaluation of 99mTc-mercaptoacetyltripeptides in mice and a baboon | |
| Jones-Wilson et al. | New hydroxybenzyl and hydroxypyridylmethyl substituted triazacyclononane ligands for use with gallium (III) and indium (III) | |
| Baker et al. | Technetium-99m complexes of EDTA analogs: Studies of the radiochemistry and biodistribution | |
| Chakravarty et al. | Technetium-99m amino acid chelates: Correlation of their physico-chemical and physiological parameters. Part I. | |
| Baldas et al. | Preparation, HPLC studies and biological behaviour of 99mTc-and 99mTcN-radiopharmaceuticals based on quinoline type ligands | |
| Djokić et al. | Chemical and biological evaluation of 99m Tc (CO) 3 and 99m Tc complexes of some IDA derivatives | |
| Bormans et al. | Evaluation of the renal excretion characteristics of technetium-99m mercaptoacetylglycyl-D-alanylglycine in healthy volunteers |